Blaine Hollinger, MD

Dr. F. Blaine Hollinger has been actively involved in hepatitis research since joining the Department of Molecular Virology and Epidemiology at Baylor College of Medicine in Houston, Texas in 1968 and the Department of Medicine (GI/Baylor Liver Center) in 1981. He is currently Professor of Medicine, Molecular Virology & Epidemiology and Director of the Eugene B. Casey Hepatitis Research Center. He is a Fellow of the IDSA, the AGA, the ACG, and the AASLD. He received the Marquis Who’s Who Lifetime Achievement Award and the American Men and Women of Science award and was a Rhodes Scholar designee for the Midwest Region. He has been an advisor and consultant on program projects, grants, and contracts related to viral hepatitis and drug therapy for the National Institutes of Health and the Food and Drug Administration (FDA) and a consultant to the Transfusion Transmitted Diseases Committee of the AABB. He served on the Blood Products Advisory Committee (BPAC) for the FDA becoming its Chairman in 1997 and again in 2010 for which he was presented with the Advisory Committee Service Award on each occasion.

Dr. Hollinger is an experienced researcher and hepatologist who has engaged in a number of national multicenter clinical trials and basic scientific projects related to viral hepatitis over the past 40 years. He has published over 275 articles, books and chapters in this field that includes the characterization and diagnosis of viral hepatitis agents, development of sensitive immunological assays, prophylaxis of hepatitis A and B, vaccine development, therapy of hepatitis B and C, studies on the immunopathogenesis and natural history of viral hepatitis, and the epidemiology of blood-borne pathogens and posttransfusion hepatitis. His current research interests are to determine how chronic HCV infection disrupts the insulin signaling pathway and interferes with the interferon response, to study the effect of HBx on viral replication that might lead to the development of a novel antiviral drug inhibitor and the prevention of hepatocellular carcinoma using human hepatocyte engrafted mice and human liver organoids to evaluate new therapeutic targets for HBV and HCV and to determine the role of occult hepatitis B in transfusion medicine. His clinic responsibilities include all aspects of acute and chronic liver disease.

Last updated on August 4th, 2022 at 12:46 pm

cross linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram